Sue-Jean Lin

Board Director

Director

Arcutis Biotherapeutics, Inc.Stevanato Group S.p.A.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 1 saleDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (2 ops.)

€676k

Latest filing published 26 Jun 2026 for Stevanato Group S.p.A.. Read the official filing

Filing timeline

BuySale

Sue-Jean Lin

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Sue-Jean Lin: trading record in brief

Sue-Jean Lin, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Arcutis Biotherapeutics, Inc. and Stevanato Group S.p.A. Between 1 June 2022 and 15 June 2026, the trades on record add up to 10 filings.

The open-market record consists of 2 sales worth €676k, with no purchase. The totals do not cover 1 filing with an undisclosed amount. Besides market trades, the filings include 6 share grants and 2 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

Most recently, on 26 June 2026, the filings show a share grant in Stevanato Group S.p.A. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.